1286 related articles for article (PubMed ID: 24450858)
21. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
22. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
23. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
24. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Barbieux S; Boyle EM; Baillet C; Demarquette H; Vermersch P; Morschhauser F; Herbaux C
Curr Res Transl Med; 2018 Sep; 66(3):87-89. PubMed ID: 30191811
[TBL] [Abstract][Full Text] [Related]
25. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
26. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
27. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
28. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
29. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
30. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
Fruman DA; Cantley LC
N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
[No Abstract] [Full Text] [Related]
31. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
[TBL] [Abstract][Full Text] [Related]
32. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
33. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Barrientos JC; Hillmen P; Salles G; Sharman J; Stilgenbauer S; Gurtovaya O; Xing G; Ruzicka B; Bhargava P; Ghia P; Pagel JM
Leuk Lymphoma; 2021 Apr; 62(4):837-845. PubMed ID: 33297794
[TBL] [Abstract][Full Text] [Related]
34. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
35. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
36. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
37. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
39. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
Hainsworth JD
Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
[TBL] [Abstract][Full Text] [Related]
40. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]